Items where authors include "Awada, A"
Article
Rugo, HS, Cortes, J, Awada, A et al. (12 more authors) (2018) Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research, 24 (14). pp. 3348-3357. ISSN 1078-0432
Başaran, GA, Twelves, C, Diéras, V et al. (2 more authors) (2018) Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews, 63. pp. 144-155. ISSN 0305-7372
Cortés, J, Rugo, HS, Awada, A et al. (16 more authors) (2017) Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (vol 165, pg 329, 2017). Breast Cancer Research and Treatment, 166 (1). pp. 327-328. ISSN 0167-6806
Cortés, J, Rugo, HS, Awada, A et al. (16 more authors) (2017) Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Research and Treatment, 165 (2). pp. 329-341. ISSN 0167-6806
Twelves, C, Cortés, J, Shaughnessy, JO et al. (16 more authors) (2017) Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial. European Journal of Cancer, 76. pp. 205-215. ISSN 0959-8049
Cortés, J, Rugo, HS, Twelves, C et al. (10 more authors) (2016) Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. SpringerPlus, 5 (1). 1033. ISSN 2193-1801
Twelves, C, Awada, A, Cortes, J et al. (6 more authors) (2016) Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer: Basic and Clinical Research, 10. pp. 77-84.
Twelves, C, Jove, M, Gombos, A et al. (1 more author) (2016) Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. Critical Reviews in Oncology/Hematology, 100. pp. 74-87. ISSN 1040-8428
Cortes, J, Hudgens, S, Twelves, C et al. (7 more authors) (2015) Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast cancer research and treatment, 154 (3). 509 - 520. ISSN 0167-6806
Kaufman, PA, Awada, A, Twelves, C et al. (7 more authors) (2015) Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 33 (6). pp. 594-601. ISSN 0732-183X
Kaufmann, PA, Cortes, J, Awada, A et al. (8 more authors) (2013) A Phase Ill, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses. Onkologie: international journal for cancer research and treatment, 36 (Suppl 7). p. 97. ISSN 0378-584X
Proceedings Paper
O'Shaughnessy, J, Rugo, H, Awada, A et al. (16 more authors) (2016) Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM). In: European Journal of Cancer. 10th European Breast Cancer Conference (EBCC-10), 09-11 Mar 2016, Amsterdam, Netherlands. Elsevier , S111-S112.